AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at the 18th Federation of European Societies for Surgery of the Hand Congress
Congress Focused on Nerve Repair in the Hand; Presentation to Highlight Use of Avance® Nerve Graft in Hand Microsurgery.
Alachua, FL (PRWEB) May 29, 2013
AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced that positive data based on clinical use of Avance® Nerve Graft will be presented in an oral presentation at the 18th Federation of European Societies for Surgery of the Hand (FESSH) Congress, May 29 to June 1, 2013 in Antalya, Turkey. The main topic of the congress will be “Current Treatment of Nerve Injuries and Disorders.” AxoGen will also host a booth to exhibit its products, including the recently CE Marked AxoGuard® Nerve Protector and AxoGuard® Nerve Connector, at the FESSH Congress.
The data being presented will report on findings from the RANGER® Registry, an on-going multi-center utilization and outcomes study for Avance® Nerve Graft, a processed nerve allograft for the repair and reconstruction of peripheral nerve segmental defects. Study investigator Bauback Safa, MD, of The Buncke Clinic in San Francisco, CA, will share findings in an oral presentation titled, “Nerve Reconstruction with Processed Nerve Allografts: Outcomes from a National Multicenter Registry,” which is based on a subset of data from the RANGER® Registry focused on nerve repair in the hand.
Dr. Safa said, “I am pleased to share the positive clinical outcomes in nerve repair of the hand that have been recorded to date in the Ranger® Registry, which is the largest multi-center study of peripheral nerve repair. Restoring proper function in the nerves of the hand has historically been very challenging, with recovery dependent on many factors. Our results with hand microsurgery using the Avance® Nerve Graft at The Buncke Clinic have been very encouraging, in terms of both clinical outcomes and the fact that the product does not require a second surgical site for autograft harvest. I look forward to contributing to the scientific session at the FESSH Congress to expand awareness of this innovative, commercially available nerve graft option.”
Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The product provides surgeons a readily-available nerve allograft to repair peripheral nerves damaged by trauma or resected during a surgical procedure.
For more information on AxoGen and its technology, please visit http://www.axogeninc.com.
About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company´s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen´s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen´s principal executive office and operations are located in Alachua, FL.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management´s current expectations or predictions of future conditions, events or results based on various assumptions and management´s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen´s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen´s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10778130.htm